MicuRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Qualified Infectious Disease Product and the Fast Track Designation under the Generating Antibiotic Incentives Now Act for contezolid tablet and contezolid acefosamil tablet and intravenous as novel new oxazolidinone antibiotics for the treatment of moderate to severe diabetic foot infection without concomitant osteomyelitis.
